Related references
Note: Only part of the references are listed.Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors
Ping Chi et al.
CLINICAL CANCER RESEARCH (2022)
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
Bruno Vincenzi et al.
CLINICAL CANCER RESEARCH (2022)
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor
Ping Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. G. Casali et al.
ANNALS OF ONCOLOGY (2022)
A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors
Arun S. Singh et al.
CLINICAL CANCER RESEARCH (2022)
Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response
Mayra Yebra et al.
CLINICAL CANCER RESEARCH (2022)
New treatment strategies for advanced-stage gastrointestinal stromal tumours
Lillian R. Klug et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial
Y. Kurokawa et al.
ANNALS OF ONCOLOGY (2022)
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
Sebastian Bauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
Suzanne George et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules
Christos Vallilas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The management of metastatic GIST: current standard and investigational therapeutics
Ciara M. Kelly et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Pimitespib is effective on cecal GIST in a mouse model of familial GISTs with KIT-Asp820Tyr mutation through KIT signaling inhibition
Takako Kihara et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2021)
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
Robin L. Jones et al.
EUROPEAN JOURNAL OF CANCER (2021)
Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate
Kenji Iida et al.
CANCER DISCOVERY (2021)
Gastrointestinal stromal tumours
Jean-Yves Blay et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
A phase Ib/II study of selinexor in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial.
Cesar Serrano et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
Yoon-Koo Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors
Anu Gupta et al.
PLOS ONE (2021)
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors A Phase 1b/2a Nonrandomized Clinical Trial
Andrew J. Wagner et al.
JAMA ONCOLOGY (2021)
Recent Progress and Challenges in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors
Toshirou Nishida et al.
CANCERS (2021)
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit inPatients WithRefractory Gastrointestinal Stromal Tumors A Phase 1b/2a Nonrandomized Clinical Trial
Andrew J. Wagner et al.
JAMA ONCOLOGY (2021)
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naive and imatinib-resistant gastrointestinal stromal tumours
Yurina Saito et al.
BRITISH JOURNAL OF CANCER (2020)
A phase II, single arm study of avelumab in combination with axitinib in patients with unresectable/metastatic gastrointestinal stromal tumor after failure of standard therapy - AXAGIST
K. Kozak et al.
ANNALS OF ONCOLOGY (2020)
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2020)
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Michael C Heinrich et al.
LANCET ONCOLOGY (2020)
NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021
Margaret von Mehren et al.
Journal of the National Comprehensive Cancer Network (2020)
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Cesar Serrano et al.
BRITISH JOURNAL OF CANCER (2019)
First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors
Akihiko Shimomura et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors
Pushpa Neppala et al.
CANCER AND METASTASIS REVIEWS (2019)
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. G. Casali et al.
ANNALS OF ONCOLOGY (2018)
A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (guadecitabine), in children and adults with wild type GIST, pheochromocytoma and paraganglioma associated with succinate dehydrogenase deficiency and HLRCC-associated kidney cancer.
Jaydira Del Rivero et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
Bruno Vincenzi et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
Sandra P. D'Angelo et al.
CLINICAL CANCER RESEARCH (2017)
PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors
Adrian M. Seifert et al.
CLINICAL CANCER RESEARCH (2017)
Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients
Sheima Farag et al.
EUROPEAN JOURNAL OF CANCER (2017)
Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors
Cesar Serrano et al.
TARGETED ONCOLOGY (2017)
An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.
G. D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
George D. Demetri et al.
Journal of the National Comprehensive Cancer Network (2017)
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
Heikki Joensuu et al.
BRITISH JOURNAL OF CANCER (2017)
UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST)
Ian Judson et al.
CLINICAL SARCOMA RESEARCH (2017)
A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors
Johanna C. Bendell et al.
CANCER INVESTIGATION (2016)
Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour
Andrew J. Wagner et al.
EUROPEAN JOURNAL OF CANCER (2016)
Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
Dong-Hoe Koo et al.
CANCER RESEARCH AND TREATMENT (2016)
Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors
Khanh Do et al.
INVESTIGATIONAL NEW DRUGS (2015)
Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study
Heikki Joensuu et al.
RADIOTHERAPY AND ONCOLOGY (2015)
First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2015)
TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
Shuichi Ohkubo et al.
MOLECULAR CANCER THERAPEUTICS (2015)
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors ( GIST) following failure of at least imatinib and sunitinib
K. N. Ganjoo et al.
ANNALS OF ONCOLOGY (2014)
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
Toshihiko Doi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in China
Chun-Yan Du et al.
EUROPEAN JOURNAL OF CANCER (2014)
Considering the role of radiation therapy for gastrointestinal stromal tumor
Kimberly S. Corbin et al.
ONCOTARGETS AND THERAPY (2014)
Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
Akira Sawaki et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2014)
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
M. A. Dickson et al.
ANNALS OF ONCOLOGY (2013)
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib
Aiping Zhou et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET ONCOLOGY (2013)
Inhibition of HSP90 molecular chaperones: moving into the clinic
Rocio Garcia-Carbonero et al.
LANCET ONCOLOGY (2013)
Gastrointestinal stromal tumours: origin and molecular oncology
Christopher L. Corless et al.
NATURE REVIEWS CANCER (2011)
Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma
R. L. Jones et al.
EJSO (2010)
Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors
Katsuhiro Kobayashi et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2009)
Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor
Toshirou Nishida et al.
CANCER SCIENCE (2008)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gastrointestinal stromal tumour
Brian P. Rubin et al.
LANCET (2007)
Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors - Response, survival, and prognostic factors
Katsuhiro Kobayashi et al.
CANCER (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
Maria Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2006)
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
CR Antonescu et al.
CLINICAL CANCER RESEARCH (2005)
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants
M Debiec-Rychter et al.
GASTROENTEROLOGY (2005)
PDGFRA activating mutations in gastrointestinal stromal tumors
MC Heinrich et al.
SCIENCE (2003)
Share Paper
